Talon Resources Targets Ontario Gold Growth After AIM Move and Eagle Lake Acquisition, CEO Says.Watch here

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHikma Pharmaceuticals Regulatory News (HIK)

Share Price Information for Hikma Pharmaceuticals (HIK)

Share Price is delayed by 15 minutes
Get Live Data
1,530.00    3.00 (0.20%)
Bid:
1,528.00
Ask:
1,530.00
Spread: 2.00 (0.131%)
Market Cap: £3.22b
HIK Live PriceLast checked at - London Stock Exchange

Intraday Hikma Pharmaceuticals Share Chart

Launch of Buyback Programme

26 Feb 2026 07:05

RNS Number : 4522U
Hikma Pharmaceuticals Plc
26 February 2026
 

HIKMA PHARMACEUTICALS PLC

LAUNCH OF BUYBACK PROGRAMME

London, 26 February 2026 - As separately announced today in its full-year results for the financial year ended 31 December 2025, Hikma Pharmaceuticals PLC (LSE: HIK) (NasdaqDubai: HIK) (LEI: 549300BNS685UXH4JI75) ("Hikma") is today commencing a buyback programme for the repurchase of its ordinary shares of £0.10 each (the "Ordinary Shares") up to the value of US $250 million (excluding stamp duty and expenses) to be executed effective immediately and completed no later than market close on 23 September 2026 (the "Buyback Programme").

· Announcing a share buyback programme of up to US $250 million (excluding stamp duty and expenses) to be executed during 2026

· Buyback reflects the Group's strong cash generation, balance sheet strength and the Board's confidence in the future growth prospects of the business

· Hikma's strategic focus remains unchanged, prioritising the creation of further shareholder value through investing in organic and inorganic growth

· The buyback has been sized to maintain balance sheet efficiency whilst leaving sufficient headroom for continued investment opportunities

The purpose of the Buyback Programme is to reduce the share capital of Hikma.

Hikma has entered into agreements with Citigroup Global Markets Limited ("Citi") and J.P. Morgan Securities plc ("JPMS plc") under which it has issued non-discretionary instructions to Citi and JPMS plc to manage the Buyback Programme in equal tranches by value and sequentially in accordance with each bank's respective period of engagement. Each of Citi and JPMS plc will act as riskless principal for the simultaneous on-sale of such shares to Hikma and will make their respective trading decisions under the Buyback Programme independently of Hikma in accordance with certain pre-set parameters and will carry out their respective instructions through the acquisition of Ordinary Shares in Hikma for subsequent repurchase by Hikma.

Hikma has instructed Citi in relation to the first tranche of repurchases of Hikma's Ordinary Shares for an aggregate purchase price of up to US $125 million (excluding stamp duty and expenses) pursuant to the Buyback Programme (the "Initial Tranche"). Purchases of the Ordinary Shares under the Initial Tranche will commence on 26 February 2026 and end no later than market close on 9 June 2026 and will be carried out on the London Stock Exchange, CBOE Europe Equities (comprising CXE and BXE), Turquoise and/or Aquis Exchange trading venues.

Hikma has instructed JPMS plc in relation to the second tranche of repurchases of Hikma's Ordinary Shares for an aggregate purchase price of up to US $125 million (excluding stamp duty and expenses) pursuant to the Buyback Programme (the "Second Tranche"), to be commenced automatically upon conclusion of the Initial Tranche and end no later than three calendar months and 10 trading days following commencement.

Any acquisitions under the Buyback Programme will be carried out within certain pre-set parameters, and in relation to any acquisitions made under the Initial Tranche and prior to the conclusion of Hikma's 2026 Annual General Meeting, will be made in accordance with the shareholder authorities granted at Hikma's Annual General Meeting on 24 April 2025 being (i) Hikma's general authority to repurchase Ordinary Shares up to a maximum number of 22,188,645 Ordinary Shares, and (ii) the waiver of Rule 9 of the City Code on Takeovers and Mergers in relation to such repurchases. The continuation of the Buyback Programme after Hikma's 2026 Annual General Meeting (whether in the Initial Tranche or the Second Tranche) will be subject to shareholder approval of equivalent buyback authorities and related waivers of certain Takeover Code obligations in respect of the Darhold Concert Party's interest in Hikma at its 2026 Annual General Meeting. All Ordinary Shares purchased under the Buyback Programme will be cancelled or held in treasury.

The Buyback Programme will be conducted within the parameters prescribed by the Market Abuse Regulation (596/2014) (as in force in the UK and as amended by the Market Abuse (Amendment) (EU Exit) Regulations 2019), the Commission Delegated Regulation (EU) 2016/1052 (as in force in the UK and as amended by the FCA's Technical Standards (Market Abuse Regulation) (EU Exit) Instrument 2019) and UK Listing Rule 9.

Any repurchase of Ordinary Shares pursuant to the Buyback Programme will be announced no later than 7:30a.m. (London time) on the business day following the calendar day on which the repurchase occurred.

Enquiries:

Susan Ringdal

EVP, Strategic Planning and Global Affairs

+44 (0)20 7399 2760/ +44 (0)7776 477050

Guy Featherstone

Director, Investor Relations

+44 (0)20 3892 4389/ +44 (0)7795 896738

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCDZGZZFKGGVZZ
Date   Source Headline
22nd Jun 20261:11 pmRNSTransaction in Own Shares
15th Jun 202612:20 pmRNSHolding(s) in Company
15th Jun 20269:40 amRNSTransaction in Own Shares
12th Jun 20269:00 amRNSHolding(s) in Company
8th Jun 202610:00 amRNSTransaction in Own Shares
2nd Jun 202612:42 pmRNSDirector/PDMR Shareholding
1st Jun 20264:16 pmRNSTotal Voting Rights
1st Jun 202612:11 pmRNSTransaction in Own Shares
27th May 202610:05 amRNSTransaction in Own Shares
26th May 202610:30 amRNSTransaction in Own Shares
18th May 202610:55 amRNSTransaction in Own Shares
15th May 20269:45 amRNSChange of Registered Office
11th May 20261:10 pmRNSTransaction in Own Shares
6th May 20263:08 pmRNSDirector/PDMR Shareholding
5th May 20269:55 amRNSTransaction in Own Shares
1st May 202610:36 amRNSTotal Voting Rights
28th Apr 20261:29 pmRNSDirector/PDMR Shareholding
27th Apr 202611:55 amRNSTransaction in Own Shares
23rd Apr 20263:42 pmRNSResult of AGM
23rd Apr 20267:00 amRNSTrading Statement
20th Apr 202610:55 amRNSTransaction in Own Shares
13th Apr 20263:29 pmRNSDirector/PDMR Shareholding
13th Apr 202611:10 amRNSTransaction in Own Shares
9th Apr 20264:43 pmRNSDirector/PDMR Shareholding
7th Apr 20269:42 amRNSTransaction in Own Shares
1st Apr 202611:11 amRNSTotal Voting Rights
30th Mar 202610:55 amRNSTransaction in Own Shares
23rd Mar 202611:00 amRNSTransaction in Own Shares
18th Mar 202610:10 amRNSAnnual Financial Report and Notice of AGM
16th Mar 20269:29 amRNSTransaction in Own Shares
16th Mar 20269:29 amRNSTransaction in Own Shares
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
11th Mar 202610:09 amRNSDirector/PDMR Shareholding
9th Mar 20267:00 amRNSTransaction in Own Shares
6th Mar 20267:00 amRNSTransaction in Own Shares
5th Mar 20267:00 amRNSTransaction in Own Shares
4th Mar 20267:00 amRNSTransaction in Own Shares
3rd Mar 20267:00 amRNSTransaction in Own Shares
2nd Mar 20264:56 pmRNSTotal Voting Rights
2nd Mar 20267:00 amRNSTransaction in Own Shares
27th Feb 20267:00 amRNSTransaction in Own Shares
26th Feb 20267:05 amRNSLaunch of Buyback Programme
26th Feb 20267:00 amRNSFinal Results, Share Buyback & Leadership Changes
4th Feb 20265:29 pmRNSStatement regarding Hikma Pharmaceuticals Plc
3rd Feb 20267:00 amRNSNotice of Results
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:50 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
19th Dec 20253:43 pmRNSDirector/PDMR Shareholding
15th Dec 20253:59 pmRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.